This clinical trial is focused on studying the treatment of strongyloidiasis, a disease caused by a parasite commonly found in tropical and subtropical regions. Many people with strongyloidiasis do not show symptoms or have mild issues like stomach problems, breathing difficulties, and skin rashes. However, in individuals with weakened immune systems, such as those taking certain medications or who have had organ transplants, the disease can lead to serious complications.

The trial will use a medication called ivermectin, which is an antiparasitic agent. The study aims to evaluate the effectiveness and safety of a single fixed dose of 18 mg ivermectin compared to a dose adjusted based on the patient’s weight. The goal is to determine if both dosing methods provide the same response in treating uncomplicated strongyloidiasis in adults with healthy immune systems.

Participants in the study will receive either the fixed dose or the weight-adjusted dose of ivermectin. The trial will monitor the participants over a period to assess the microbiological cure, which means checking if the parasite is eliminated from the body, and to ensure the treatment is safe. The study will help understand the best way to use ivermectin for treating strongyloidiasis effectively.